ADC & cancer drugs stocks
ADC·항암제
What are ADC & cancer drugs stocks in Korea?
The ADC & cancer drugs theme on jonbur groups 12 Korean stocks listed on KOSPI and KOSDAQ, worth ₩100T in total. On Oct 30, 2026 the group moved up 5.71% (weighted by market value); the largest members are Samsung Biologics, Alteogen, Yuhan.
Key facts
- Stocks
- 12
- Total market value
- ₩100T
- Day's move
- +5.71%
- As of
- Oct 30, 2026
- Largest members
- Samsung Biologics, Alteogen, Yuhan
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Yuhan | Oct 28Preliminary | ₩586B | +2.8% | ₩35B | +57.8% | −48.0% | 5.9%3.9% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| ABL Bio | Expected around Nov 11 | ||||||
| Eutilex | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| LigaChem Biosciences | Expected around Nov 14 | ||||||
| HLB Pharmaceutical | Expected around Nov 14 | ||||||
| GemVax & KAEL | Expected around Nov 14 | ||||||
| ImmuneOncia Therapeutics | Expected around Nov 14 | ||||||
| HLB Global | Expected around Nov 14 | ||||||
| Oncocross | Expected around Nov 14 | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 9.1%
- Above 60-day average
- 27.3%
- RSI above 70
- 0%
- RSI below 30
- 0%
- 52-week highs
- 0
- 52-week lows
- 3
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
Across the 11 members of the ADC and cancer drugs theme, breadth is weak, with only 9.1% trading above their 20-day averages and 27.3% above their 60-day averages. No member is at an RSI extreme, and none is at a 52-week high, while 3 are at 52-week lows. The equal-weighted member index sits below its cloud, with short- and medium-term readings both labeled bearish (7 bearish signals each against 0 bullish) and an RSI of 37.5.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
Creators talking about this
ADC & cancer drugs
−13.92%ADC·항암제
ADC & cancer drugs is a Korean stock-market theme covering antibody-drug conjugates, which link an antibody to a cytotoxic payload to target cancer cells, along with other oncology drug developers and related contract manufacturing and platform technologies. Korean investors tend to group these companies together because the sector is closely tied to biopharma licensing deals with global pharmaceutical firms and to the technology transfer and manufacturing capacity that supports them. Stocks in this theme often move together on news about clinical trial results, international partnerships, or regulatory milestones.
12 companies · 2 up · 1 flat · 9 down
- Traded value
- ₩369B
- Value vs 20-day average
- 1.19×
- Top gainer
- Samsung Biologics +7.36%
- Largest company
- Samsung Biologics ₩69T
Companies in this theme
| Company | Price | Monthly | Traded value | Market cap | NPS |
|---|
Source: KRX statistical information